CREDIT AGREEMENT dated as of December 23, 2016, and as amended as of July 31, 2018 amongCredit Agreement • August 24th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledAugust 24th, 2018 Company Industry JurisdictionCREDIT AGREEMENT (this “Agreement”) dated as of December 23, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and as Collateral Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndication Agent, and U.S. BANK NATIONAL ASSOCIATION, PNC BANK, NATIONAL ASSOCIATION, FIFTH THIRD BANK, ZIONS FIRST NATIONAL BANK, a division of ZB, N.A., and SILICON VALLEY BANK, as Co-Documentation Agents.
AGREEMENT AND PLAN OF MERGER by and amongMerger Agreement • August 24th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledAugust 24th, 2018 Company Industry JurisdictionThis Agreement and Plan of Merger (as may be amended from time to time, this “Agreement”) is made and entered into as of May 25, 2018, by and among: Myriad Genetics, Inc., a Delaware Corporation (“Parent”); Cinnamon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); Counsyl, Inc., a Delaware corporation (the “Company”); and Fortis Advisors LLC, as the Securityholders’ Representative. Certain capitalized terms used in this Agreement are defined in Exhibit A.